Sperm Separation Technology Adds to CooperSurgical’s Leading Fertility Products and Services.
TRUMBULL, CONN., June 10, 2024 — CooperSurgical today announced that it has acquired ZyMōt Fertility, a subsidiary of DxNow, Inc. ZyMōt’s global presence commercializing a first-of-its-kind sperm separation device will add to CooperSurgical’s portfolio of assisted reproductive technology (ART) products and services.
“We are excited to welcome ZyMōt into the CooperSurgical family,” said Holly Sheffield, CooperSurgical President. “This product strengthens our leadership in fertility and reaffirms our commitment to providing industry-leading technology to the healthcare providers who help patients realize their dreams of family. ZyMōt® Sperm Separation Devices will be an excellent addition to our fertility solutions portfolio.”
ZyMōt Sperm Separation Devices use a patented approach to separate motile sperm from non-motile sperm in a semen sample. Motile sperm are more likely to help patients achieve a successful pregnancy.1 Alongside CooperSurgical’s existing, comprehensive portfolio of fertility solutions, digital services, and cutting-edge ART media that supports every step in the ART journey, ZyMōt will equip more clinics around the world with the innovative technologies of today’s industry to conceive healthy babies.
References
1. M. C. S. (2022, May 13). Healthy sperm: Improving your fertility. www.Mayoclinic.org. Retrieved May 10, 2024, from https://www.mayoclinic.org/healthy-lifestyle/getting-pregnant/in-depth/fertility/art-20047584#:~:text=To%20reach%20and%20fertilize%20an,The%20more%20the%20better.
About CooperSurgical
CooperSurgical is a leading fertility and women’s healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most in life. CooperSurgical is at the forefront of delivering innovative assisted reproductive technology (ART) and genomic solutions that enhance the work of ART professionals to the benefit of families. We currently offer over 600 clinically relevant medical devices to women’s healthcare providers, including testing and treatment options.
CooperSurgical is a wholly-owned subsidiary of CooperCompanies (Nasdaq: COO). CooperSurgical, headquartered in Trumbull, CT, produces and markets a wide array of products and services for use by women’s health care clinicians. More information can be found at www.coopersurgical.com.
About CooperCompanies
CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on improving lives one person at a time. The Company operates through two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, improving the vision of millions of people every day. CooperSurgical is a leading fertility and women’s health company dedicated to assisting women, babies and families at the healthcare moments that matter most. Headquartered in San Ramon, CA, CooperCompanies (“Cooper”) has a workforce of more than 15,000 with products sold in over 130 countries. For more information, please visit www.coopercos.com.
Forward-Looking Statements
This press release contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. Statements relating to plans, prospects, goals, strategies, future actions, events or performance and other statement of which are other than statements of historical fact, including statements regarding the benefits of the acquisition of ZyMōt® Fertility assets, synergies and strategic plans related to the acquired business, and other financial expectations related to the acquisition. To identify these statements, look for words like “believes,” “outlook,” “probable,” “expects,” “may,” “will,” “should,” “could,” “seeks,” “intends,” “plans,” “estimates” or “anticipates” and similar words or phrases. Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Among the factors that could cause actual results and future actions to differ materially from those described in forward-looking statements are: difficulties in integrating operations, adverse changes in the global or regional general business, political and economic conditions including the impact of continuing uncertainty and instability of certain countries, man-made or natural disasters, that could adversely affect our global markets, and the potential adverse economic impact and related uncertainty caused by these items; uncertainties in contractual relationships and pending transactions; changes in legal and regulatory requirements; and other factors described in the Securities and Exchange Commission filings for CooperCompanies (Nasdaq: COO), including the Annual Report on Form 10-K for the fiscal year ended October 31, 2023, as such disclosures may be updated in annual and quarterly filings. We caution investors that forward-looking statements reflect our analysis only on their stated date. We disclaim any intent to update them except as required by law.
Contact:
CooperSurgical
[email protected]
